Wave Life Sciences to discontinue development of suvodirsen for DMD
Category: #health  By Pankaj Singh  Date: 2019-12-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

Wave Life Sciences to discontinue development of suvodirsen for DMD

The results from the clinical study rendered no change from baseline in dystrophin expression

Clinical stage genetic medicines company- Wave Life Sciences Ltd. has reportedly announced the halt of suvodirsen development for patients suffering from Duchenne Muscular Dystrophy who have been diagnosed with mutations amenable to exon 51 skipping, on the basis of the interim analysis during the Phase 1 open-label extension (OLE) trial.

Apparently, the results recorded no difference in dystrophin expression from baseline, when measured with western blot when given either 5 mg/kg or 3.5 mg/kg weekly doses of suvodirsen. Safety concerns or emerging safety signals were not observed.

Due to the aforementioned observations, the company has decided to discontinue the two suvodirsen trials with immediate effect, the Phase 2/3 DYSTANCE 51 trial and the OLE study. Patients are required to undergo a final follow-up visit; however, no further doses and muscle biopsies will be administered.

The analysis was derived from a multicenter suvodirsen OLE study in volunteers who had previously registered in the Phase 1 tolerability and safety study. Follow-up volunteers had enrolled in the OLE and were for the target doses of either 3.5 mg/kg or 5 mg/kg.

For the record, before the initial dosing in the OLE, a biopsy examination of the deltoid muscle was carried out and according to the data cut-off for the provisional analysis, the follow-up biopsies of the deltoid muscle were available for 27 of the 36 patients.

For the 5 mg/kg weekly infusion period, 10 patients obtained follow-up biopsies at twelve weeks while follow up muscle biopsies at twenty-two weeks was received by 9 patients. Eight patients got the twenty-two week follow up muscle biopsies within the 3.5 mg/kg weekly infusion arm. As a part of the interim analysis, biopsies from both the timepoints were analyzed.

About Suvodirsen

Wave Life Science announced the clinical development of suvodirsen in November 2017 and completed a Phase 1 safety and tolerability study by early 2019. It is an investigational stereopure oligonucleotide initially developed for the treatment of patients suffering from DMD who have genetic mutations amenable to exon 51 skipping.

 

Source Credits: https://ir.wavelifesciences.com/news-releases/news-release-details/wave-life-sciences-announces-discontinuation-suvodirsen

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Construction sector accountable for 37% of carbon emissions, UN report
Construction sector accountable for 37% of carbon emissions, UN report
By Pankaj Singh

A new research by the United Nations shows a grim picture of the climate situation. The report states that 37% of energy-related carbon dioxide emissions are coming from the construction sector. According to the UN, lockdowns imposed worldwide durin...

Alaska Airlines launches new investment arm to develop mobility tech
Alaska Airlines launches new investment arm to develop mobility tech
By Pankaj Singh

Alaska Airlines, a major American airline, has introduced a new venture capital subdivision called Alaska Star Ventures. The launch comes at a time when the aviation sector is looking to develop technologies that help decarbonize air travel. Alaska ...

Bettervest invests in Oakridge Rooftops to support solar projects
Bettervest invests in Oakridge Rooftops to support solar projects
By Pankaj Singh

Oakridge Rooftops Pvt. Ltd., a solar energy company based in India, has reportedly secured funding from Germany-based crowdfunding platform, Bettervest Gmbh. The solar firm has raised the funding for urban solar projects in New Delhi. Oakridge CEO, ...